1h Free Analyst Time
The chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7.19 billion during 2023-2028, accelerating at a CAGR of 6.24% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of COPD, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.
The chronic obstructive pulmonary disease drugs market is segmented as below:
By Product
- Combination therapy
- Monotherapy
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online pharmacies
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the chronic obstructive pulmonary disease drugs market covers the following areas:
- Chronic obstructive pulmonary disease drugs market sizing
- Chronic obstructive pulmonary disease drugs market forecast
- Chronic obstructive pulmonary disease drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global chronic obstructive pulmonary disease drugs market: AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., Exela Pharma Sciences LLC, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva, Inc., Lupin Ltd., Merck and Co. Inc., Mundipharma International Ltd., Novartis AG, Philip Morris International Inc., SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Vertex Pharmaceuticals Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is expanding research in curative approaches."
According to the report, one of the major drivers for this market is the rising prevalence of copd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Cadila Pharmaceuticals Ltd.
- CHIESI Farmaceutici SpA
- Cipla Inc.
- Exela Pharma Sciences LLC
- GlaxoSmithKline Plc
- Glenmark Pharmaceuticals Ltd.
- Innoviva Inc.
- Lupin Ltd.
- Merck and Co. Inc.
- Mundipharma International Ltd.
- Novartis AG
- Philip Morris International Inc.
- SHIONOGI Co. Ltd.
- Sumitomo Pharma Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Theravance Biopharma Inc.
- Vertex Pharmaceuticals Inc.
- Viatris Inc.
